Quizartinib is a second-generation TKI with increased potency and selectivity for FLT3 and has shown promise in terms of improved remission rates and overall survival in relapsed/refractory FLT3-mutated AML patients [6,7,8]. The gene discussed is FLT3; the disease is acute myeloid leukemia.